Novartis (NOVN.SW) Stock Price

Currency:

Novartis Price

🇨🇭SIX·CLOSED

157.33USD

Market closed

Today +/-

-7.80 USD

Today %

-4.84 %

PRO

Novartis (NOVN.SW) — ISIN CH0012005267. The Novartis stock price was 157.33 USD in 2026. Revenue was 58.17 B USD. Earnings were 18.23 B USD. P/E ratio was 16.87. Novartis operates in the Health sector.

Novartis stock price

Ex-Dividend

Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Novartis over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Novartis stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Novartis's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Novartis Stock Price History

Date	Novartis Price
3/6/2026	157.33 USD
3/5/2026	165.13 USD
2/27/2026	167.79 USD
2/26/2026	167.58 USD
2/25/2026	167.58 USD
2/23/2026	163.29 USD
2/20/2026	163.19 USD
2/19/2026	164.91 USD
2/18/2026	165.37 USD
2/17/2026	164.32 USD
2/16/2026	163.31 USD
2/13/2026	161.97 USD
2/12/2026	159.64 USD
2/11/2026	157.44 USD
2/10/2026	157.12 USD
2/9/2026	157.46 USD
2/6/2026	152.45 USD
2/5/2026	152.75 USD

API Docs Get API Key

Novartis Revenue, EBIT, Net Income

3 Years
5 Years
10 Years
25 Years
Max

Unlock the full history with 30+ years of data and forecast estimates.

Unlock all data — PRO

Revenue

EBIT

Net Income

Details

API Docs Get API Key

Novartis Income Statement, Balance Sheet, Cash Flow Statement

Last updated Mar 7, 2026, 5:35 AM

REVENUE (B USD)

REVENUE GROWTH (%)

GROSS MARGIN (%)

GROSS INCOME (B USD)

NET INCOME (B USD)

NET INCOME GROWTH (%)

DIVIDEND (USD)DIV. (USD)

DIVIDEND GROWTH (%)DIV. GROWTH (%)

SHARES (B)

DOCUMENTS

1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e	2027e	2028e	2029e	2030e	2031e
27.76	30.44	29.31	21.51	21.88	21.6	21.22	18.76	18.63	24.86	28.4	31.32	35.11	38.95	42.58	45.1	51.56	59.38	57.56	52.72	53.63	50.36	49.39	43.36	46.02	48.62	49.9	43.97	43.38	46.66	51.72	56.33	58.17	60.94	64.31	66.85	70.26	69.76
–	9.67	-3.71	-26.61	1.70	-1.27	-1.78	-11.56	-0.71	33.47	14.23	10.27	12.09	10.94	9.34	5.92	14.32	15.15	-3.06	-8.42	1.74	-6.11	-1.93	-12.20	6.13	5.67	2.62	-11.87	-1.36	7.57	10.85	8.91	3.27	4.76	5.53	3.95	5.10	-0.71
56.88	57.66	58.73	68.42	68.29	69.75	71.39	75.08	76.08	76.30	74.41	73.63	73.19	71.67	73.14	73.00	71.90	68.03	67.42	68.55	67.66	65.99	64.89	69.06	70.54	71.35	71.14	74.10	74.15	74.24	75.22	75.82	73.42	70.08	66.41	63.89	60.79	61.22
15.79	17.55	17.21	14.72	14.94	15.07	15.15	14.09	14.17	18.97	21.13	23.06	25.69	27.92	31.15	32.92	37.07	40.39	38.81	36.14	36.29	33.23	32.05	29.95	32.46	34.69	35.5	32.58	32.16	34.64	38.91	42.71	42.71	42.71	42.71	42.71	42.71	42.71
2.67	3.57	1.86	3.6	4.15	4.43	4.27	4.16	4.22	5.02	5.37	6.13	7.18	11.95	8.2	8.4	9.79	9.11	9.27	9.18	10.21	17.78	6.71	7.7	12.61	11.73	8.07	24.02	6.96	14.85	11.94	13.98	18.23	19.55	21.84	22.63	23.81	23.82
–	33.76	-47.82	92.97	15.35	6.85	-3.59	-2.53	1.22	19.00	6.96	14.26	17.05	66.49	-31.40	2.50	16.60	-6.95	1.72	-1.02	11.28	74.17	-62.26	14.76	63.72	-6.97	-31.20	197.58	-71.05	113.52	-19.59	17.11	30.39	7.23	11.68	3.63	5.22	0.04
-	-	-	-	-	-	-	-	-	-	-	-	1.15	1.35	1.60	2.00	2.10	2.20	2.25	2.30	2.45	2.60	2.70	2.75	2.80	2.85	2.95	3.00	3.10	3.20	3.30	3.50	3.70	5.96	6.84	-	-	-
–	–	–	–	–	–	–	–	–	–	–	–	–	17.39	18.52	25.00	5.00	4.76	2.27	2.22	6.52	6.12	3.85	1.85	1.82	1.79	3.51	1.69	3.33	3.23	3.12	6.06	5.71	61.08	14.77	–	–	–
2.67	2.72	2.75	2.75	2.65	2.66	2.62	2.58	2.57	2.51	2.37	2.34	2.36	2.33	2.28	2.28	2.3	2.41	2.45	2.48	2.47	2.44	2.4	2.37	2.34	2.32	2.3	2.26	2.2	2.09	2.04	1.96	1.96	1.96	1.96	1.96	1.96	1.96
–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Novartis generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Novartis retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Novartis's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Novartis has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Novartis's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

ASSETS

CASH BALANCE (B USD)

RECEIVABLES (B USD)

OTHER RECEIVABLES (B USD)OTHER REC. (B USD)

INVENTORIES (B USD)

OTHER CURRENT ASSETS (B USD)OTHER CURRENT LIAB. (B USD)

CURRENT ASSETS (B USD)

TANGIBLE ASSETS (B USD)

LONG-TERM INVESTMENTS (B USD)LONG-T. INVEST. (B USD)

LONG-TERM RECEIVABLES (B USD)LONG-T. REC. (B USD)

INTANGIBLE ASSETS (B USD)INTANGIBLE ASSETS (B USD)

GOODWILL (B USD)

OTHER NON-CURRENT ASSETS (B USD)OTHER NON-CURRENT ASSETS (B USD)

NON-CURRENT ASSETS (B USD)

TOTAL ASSETS (B USD)

LIABILITIES

COMMON STOCK (B USD)

ADDITIONAL PAID-IN CAPITAL (M USD)

RETAINED EARNINGS (B USD)

OTHER EQUITY (M USD)OTHER EQUITY (M USD)

UNREALIZED GAINS/LOSSES (M USD)UNREAL. GAINS/LOSSES (M USD)

EQUITY (B USD)

LIABILITIES (B USD)

PROVISIONS (B USD)

OTHER SHORT-TERM LIABILITIES (B USD)OTHER SHORT-TERM LIAB. (B USD)

SHORT-TERM DEBTS (B USD)SHORT-TERM DEBTS (B USD)

SHORT-TERM PORTION OF LONG-TERM DEBTS (B USD)LONG-TERM DEBT PORTION (B USD)

SHORT-TERM RECEIVABLES (B USD)SHORT-TERM REC. (B USD)

LONG-TERM LIABILITIES (B USD)LONG-T. LIAB. (B USD)

DEFERRED TAXES (B USD)

OTHER LIABILITIES (B USD)OTHER LIAB. (B USD)

LONG-TERM LIABILITIES (B USD)LONG-T. LIABILITIES (B USD)

DEBT (B USD)

TOTAL CAPITAL (B USD)

1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025

9.62	13.33	14.2	9.23	10.32	10.27	12.75	13.35	12.6	13.26	13.89	10.93	7.96	13.2	6.12	17.45	8.13	5.08	7.97	9.1	13.5	5.3	7.55	9.35	15.72	11.23	11.29	28.11	18.73	14.07	13.35	11.59
5.45	5.42	5.04	4.02	4.23	4.43	3.43	3.23	3.71	4.38	4.85	5.34	6.16	6.65	7.03	8.31	9.87	10.32	10.06	9.91	8.28	8.18	8.2	8.6	8.74	8.3	8.22	8.01	8.07	7.11	7.42	8.94
0	0	0	0	2.08	2.61	1.25	1.35	1.29	1.1	1.35	1.22	0	0	0	0	0	2.05	2.48	2.72	1.98	2.37	2.01	2.5	2.3	2.04	1.82	1.62	1.83	2.27	2.12	0.21
6.27	6.38	5.94	4.48	4.87	4.33	2.63	2.48	2.98	3.35	3.56	3.73	4.5	5.46	5.79	5.83	6.09	5.93	6.74	7.27	6.09	6.23	6.26	6.87	6.96	5.98	7.13	6.67	7.18	5.91	5.72	6.27
2.2	2.05	1.89	2.24	0.3	0.17	0.41	0.19	0.33	0.19	0.27	0.22	2.79	2.13	1.95	2.1	2.59	0.71	0.75	1.55	7.71	0.76	0.92	0.89	1.85	1.95	1.21	1.32	1.12	1.12	1.09	3.46
23.53	27.17	27.07	19.96	21.81	21.81	20.46	20.6	20.91	22.27	23.92	21.44	21.4	27.43	20.88	33.69	26.69	24.08	28	30.54	37.56	22.85	24.93	28.21	35.56	29.5	29.67	45.72	36.91	30.48	29.7	30.46
13.59	13.41	11.95	7.93	8.28	7.34	5.61	5.46	6.35	7.6	8.5	8.68	10.95	12.63	13.1	14.08	15.84	15.63	16.94	18.2	15.98	15.98	15.64	16.46	15.7	13.75	13.94	13.11	12.2	10.92	10.87	12.35
1.55	2.03	2.15	4.05	5.39	5.48	1.88	5.36	7.82	8.36	9.21	9	8.42	6.95	18.78	20.43	10.23	9.56	9.51	10.1	9.44	16.58	15.4	16.65	9.79	10.54	11.61	2.27	1.61	1.83	1.13	2.45
0.06	0.06	0.18	0	0.12	0.07	0	0	0	0	0	0	0	0	0	0	0	0	0.44	0.65	0.71	1.2	1.1	0.97	0.91	0.62	0.92	0.97	0.95	0.99	1.01	0
0.14	0.16	0.17	1.81	0.65	1.06	1.97	2.56	2.7	3.23	3.73	6.02	21.23	21.25	9.53	10.33	35.23	31.97	30.33	27.84	23.83	34.22	31.34	30	38.72	28.79	36.81	34.18	31.64	26.88	26.92	29.41
0	0.43	0.91	0	1.29	0.96	1.65	1.38	1.71	1.48	1.9	7.28	0	0	11.29	12.04	29.69	29.94	31.09	31.03	29.31	31.17	30.98	31.75	35.29	26.52	30	29.6	29.3	23.34	24.76	25.57
0.41	0.86	0.84	2.78	3.4	4.49	4.58	4.87	5.73	6.38	5.24	5.32	6.01	7.2	4.72	4.94	5.65	6.31	7.87	7.9	8.55	9.56	10.73	9.05	9.59	8.65	4.83	5.95	4.85	5.51	7.86	10.71
15.76	16.94	16.2	16.57	19.13	19.4	15.69	19.64	24.32	27.04	28.57	36.29	46.6	48.02	57.42	61.81	96.63	93.41	96.19	95.71	87.83	108.71	105.19	104.87	110	88.87	98.11	86.08	80.54	69.46	72.54	80.49
39.29	44.12	43.27	36.53	40.94	41.21	36.15	40.23	45.23	49.32	52.49	57.73	68.01	75.45	78.3	95.51	123.32	117.5	124.19	126.25	125.39	131.56	130.12	133.08	145.56	118.37	127.78	131.8	117.45	99.95	102.25	110.95

1.07	1.22	1.08	0.99	1.05	0.91	0.9	0.87	1.03	1.02	1.01	0.99	0.99	0.99	0.96	0.96	0.96	1.02	1	1	1	0.99	0.97	0.97	0.94	0.94	0.91	0.9	0.89	0.83	0.79	0.77
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
16.13	20.97	19.61	17.4	21.89	22.58	22.09	24.69	27.5	29.53	30.33	32.14	40.26	48.41	49.47	56.56	62.36	64.95	68.23	73.43	69.87	80.38	81.15	77.64	82.19	59.27	57.16	70.99	63.54	49.65	46.56	45.41
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-4,684	-7,560	-4,726	-4,658	-4,656	-1,419	-4,187	-4,798	-3,608	-3,080	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	461	348	386	206	0	0	0	-198	-158	-175	0
17.2	22.19	20.69	18.39	22.94	23.49	22.98	25.56	28.53	30.55	31.34	33.14	41.25	49.4	50.43	57.52	63.32	65.97	69.23	74.43	70.87	77.15	74.91	74.27	78.68	55.55	56.65	67.7	59.43	46.71	44.1	46.18
1.77	1.8	1.48	1.2	1.12	1.24	1	1.09	1.27	1.67	2.02	1.96	2.49	3.02	3.4	4.01	4.79	4.99	5.59	6.15	5.42	5.67	4.87	5.17	5.56	5.42	5.4	5.55	5.15	4.93	4.57	4.46
0	0	0	0	3.44	3.79	2.8	2.69	3	3.86	3.39	2.2	2.22	0	0	0	0	4.03	4.07	4.29	4.4	4.37	4.17	4.81	5.11	5.06	5.34	5.1	5.33	5.15	5.24	0
6.12	5.13	7.13	5.36	1.93	1.22	1.08	1.72	1.52	1.51	2.62	4.27	4.97	8.71	8.25	10.23	11.29	7.78	8.6	9.26	10.59	8.1	7.38	8.22	9.33	10.69	12.44	13.05	12.05	10	10.56	17.04
6.69	5.01	4.8	4.35	4.07	4.2	2.3	2.28	2.41	2.24	3.14	5.77	5.22	4.89	4.84	5.2	8.49	5.57	3.77	4.08	3.57	3.92	5.61	4.84	6.43	4.84	7.32	3.61	3.64	3.89	4.73	0
0.19	0.34	0.61	0.76	0.35	0.5	0.05	0.78	0.11	0.05	0.68	1.12	1.34	0.02	0.02	0.03	0.1	0.78	2.01	2.59	2.99	1.66	0.18	0.36	3.19	2.25	2.56	2.9	2.49	2.42	3.59	5.78
14.77	12.28	14.02	11.67	10.91	10.95	7.23	8.56	8.31	9.32	11.85	15.33	16.23	16.64	16.5	19.47	24.66	23.15	24.05	26.37	26.97	23.71	22.21	23.4	29.61	28.26	33.06	30.21	28.66	26.39	28.69	27.28
2.85	4.85	4.17	2.47	2.07	1.54	1.42	1.51	2.74	3.19	2.74	1.32	0.66	0.68	2.18	8.68	14.36	13.86	13.78	11.24	13.8	16.33	17.9	23.22	22.47	22.06	27.98	24.52	21.78	20.03	22.93	29.59
0.83	0.99	-0.03	1.1	2.07	2.29	2.17	2.34	2.83	3.14	2.34	3.47	5.29	4.47	4.14	4.41	7.69	6.76	7.29	6.9	6.1	6.36	6.66	5.17	7.48	5.87	3.14	3.07	2.69	2.25	2.42	3.4
3.42	3.55	4.23	2.8	2.89	2.88	2.39	2.31	2.88	3.15	4.25	4.45	4.53	4.27	5.04	5.49	6.84	7.79	9.81	7.27	7.67	8.04	8.47	7.06	7.32	6.63	6.93	6.17	4.91	4.52	4.08	4.13
7.09	9.39	8.37	6.37	7.02	6.71	5.97	6.16	8.46	9.48	9.32	9.24	10.48	9.42	11.36	18.57	28.89	28.41	30.88	25.41	27.57	30.73	33.02	35.45	37.26	34.56	38.05	33.77	29.37	26.81	29.43	37.12
21.86	21.67	22.39	18.04	17.94	17.66	13.2	14.71	16.77	18.8	21.17	24.57	26.71	26.06	27.86	38.04	53.55	51.56	54.93	51.78	54.54	54.43	55.23	58.85	66.87	62.82	71.11	63.97	58.03	53.2	58.12	64.4
39.06	43.85	43.08	36.42	40.88	41.15	36.18	40.27	45.29	49.35	52.51	57.7	67.97	75.45	78.29	95.56	116.87	117.52	124.16	126.21	125.41	131.58	130.14	133.12	145.55	118.37	127.76	131.68	117.46	99.9	102.22	110.58

Details

Balance Sheet

ⓘ

What Is the Balance Sheet?

The balance sheet is a financial snapshot of Novartis at a specific point in time. It follows the fundamental equation: Assets = Liabilities + Shareholders' Equity. Unlike the income statement (which covers a period), the balance sheet tells you what the company owns, what it owes, and what belongs to shareholders at a given date.

Assets

Current assets (cash, receivables, inventory) can be converted to cash within 12 months and indicate short-term liquidity. Non-current assets (property, equipment, intangible assets, goodwill) represent long-term investments. A high proportion of cash and short-term investments gives Novartis financial flexibility to weather downturns, fund acquisitions, or return capital to shareholders.

Liabilities

Current liabilities (accounts payable, short-term debt) are obligations due within one year. Non-current liabilities (long-term debt, pension obligations) are due further out. Key ratio to watch: the debt-to-equity ratio (Total Debt ÷ Shareholders' Equity). A ratio below 1.0 is generally healthy, meaning the company is funded more by equity than debt. Highly leveraged companies amplify both gains and losses.

Shareholders' Equity

Equity is the residual value belonging to shareholders after all debts are paid. It includes retained earnings (accumulated profits not paid out as dividends) and paid-in capital. Rising equity year over year is a positive sign — it means Novartis is building book value. Declining equity, especially when driven by losses or heavy share buybacks funded by debt, warrants closer scrutiny.

Key Ratios to Derive

From the balance sheet, you can calculate the current ratio (current assets ÷ current liabilities; above 1.5 is comfortable), book value per share (equity ÷ shares outstanding), and return on equity (net income ÷ equity; above 15 % is strong). Tracking these ratios over time reveals whether Novartis is strengthening or weakening its financial position.

NET INCOME (B USD)

DEPRECIATION AND AMORTIZATION B USDDEPRECIATION (B USD)

DEFERRED TAXES (M USD)

CHANGES IN WORKING CAPITAL (B USD)CHANGES IN WORKING CAPITAL (B USD)

NON-CASH ITEM (B USD)

PAID INTEREST (M USD)

PAID TAXES (B USD)

Net Cash Flow from Operating Activities (B USD)NET CASH FLOW FROM OPERATING ACTIVITIES (B USD)

CAPITAL EXPENDITURES (M USD)

CASH FLOW FROM INVESTING ACTIVITIES (B USD)CASH FLOW FROM INVESTING ACTIVITIES (B USD)

CASH FLOW FROM OTHER INVESTING ACTIVITIES (B USD)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B USD)

INTEREST INCOME AND EXPENSES (M USD)

NET DEBT CHANGE (B USD)NET DEBT CHANGE (B USD)

Net change in equity (M USD)NET CHANGE IN EQUITY (M USD)

CASH FLOW FROM FINANCING ACTIVITIES (B USD)CASH FLOW FROM FINANCING ACTIVITIES (B USD)

OTHER ITEMS OF FINANCING CASH FLOWS (B USD)CASH FLOW FROM OTHER FINANCING ACTIVITIES (B USD)

TOTAL DIVIDENDS PAID (M USD)

NET CHANGE IN CASH FLOW (B USD)

FREE CASH FLOW (M USD)

SHARE-BASED COMPENSATION (M USD)

1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
2.67	3.57	1.86	4.68	4.15	4.43	4.27	4.16	4.22	5.02	5.38	6.07	6.83	6.54	8.16	8.45	9.97	9.25	9.38	9.31	10.73	7.03	6.7	7.5	12.8	7.15	8.07	24.02	6.96	8.57	11.94	13.97
1.38	1.6	1.44	0.89	0.96	1	0.89	1.04	1.16	1.28	1.39	1.68	1.92	2.86	2.67	2.3	3.42	5.79	4.92	4.41	4.68	5.47	6.04	4.74	5.21	5.83	6.46	6.11	7.18	8.28	4.6	5.33
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
-0.53	-0.03	1.83	-2.34	-1.63	-1.11	-1.05	-0.71	-0.72	-0.3	-1.05	-0.57	-2.06	-2.2	-2.92	-1.71	-2.07	-4.24	-3.45	-3.9	-4.08	-4.7	-3.51	-1.6	-1.42	-2.72	-4.73	-3.35	-4.3	-4.79	-4.44	-6.29
0.17	-0.29	-1.31	0	0.57	0.26	0.4	-0.13	0.01	0.65	0.88	0.87	2.07	9.61	2.49	3.93	3.59	4.53	4.35	4.35	2.57	4.92	2.9	2.6	-1.56	4.2	4.57	-10.97	5.26	3.27	6.56	7.24
0	0	0	344	942	542	717	231	154	240	274	313	277	255	268	654	525	640	594	609	668	646	723	697	816	793	703	664	696	751	855	981
0	0	0	0.85	1.27	1.12	1.29	0.82	0.69	0.84	1.08	1.35	1.72	1.58	1.94	1.62	2.62	2.44	2.02	2.05	2.18	2.45	2.11	1.49	1.51	1.88	1.83	2.34	1.98	2.79	2.26	2.56
3.69	4.85	3.84	3.23	4.04	4.59	4.51	4.35	4.67	6.65	6.6	8.05	8.76	16.81	9.66	12.19	14.07	14.31	14.19	13.17	13.9	11.9	11.48	12.62	14.27	13.63	13.65	15.07	14.24	14.46	17.62	19.14
-2,229	-3,916	-1,984	-1,072	-1,088	-912	-801	-1,381	-1,033	-1,543	-1,450	-1,515	-2,230	-3,133	-2,316	-2,733	-2,232	-2,387	-3,068	-3,378	-3,404	-3,505	-2,879	-2,294	-2,648	-2,257	-2,585	-2,971	-2,671	-2,753	-3,814	-3,900
-5.64	-2.33	0.19	-1.81	-2.65	-2.01	-0.13	-2.77	-2.56	-1.3	-3.22	-7.45	-6.36	-6.24	-10.37	-14.22	-15.76	-0.79	-5.68	-3.35	0.88	-10.78	-3.44	-3.12	-5.59	-2.23	-13.18	4.21	1.47	5.6	-7.51	-4.88
-3.41	1.59	2.18	-0.73	-1.56	-1.1	0.67	-1.39	-1.52	0.25	-1.77	-5.93	-4.13	-3.11	-8.05	-11.49	-13.52	1.6	-2.61	0.03	4.29	-7.28	-0.56	-0.83	-2.94	0.03	-10.6	7.18	4.14	8.35	-3.7	-0.98
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1.92	0.14	-0.51	-0.98	-1.57	-0.31	-0.9	0.97	0.49	-0.28	0.68	2.03	-2.87	-2.16	1.3	6.54	8.28	-2.8	-0.46	-1.33	3.32	1.96	2.06	4.1	4.18	-4.96	7.07	-5.99	-2.56	-1.94	4.39	2.43
278	620	32	-230	499	-1,276	-690	123	-2,880	-3,731	-1,760	-164	254	-4,599	-473	263	419	-3,465	-91	-1,237	-4,515	-4,490	-895	-5,238	-1,336	-5,332	-2,094	-3,004	-10,552	-8,566	-8,301	-9,185
1.57	-0.03	-1.42	-5.59	-2.22	-2.87	-2.82	-0.21	-3.61	-5.76	-3	-0.27	-4.93	-9.32	-2.57	2.81	4.12	-15.02	-6.68	-8.77	-8.15	-9.18	-5.31	-7.73	-4.24	-13.63	-2.21	-16.26	-20.56	-14.28	-11.74	-14.87
0	0	0	-3.42	0	0	0	0	0	-0.03	-0.03	-0.03	-0.27	0.04	-0.05	-0.05	-0.1	-3.39	-0.09	-0.1	-0.14	-0	0	-0.1	-0.12	3.31	-0.2	0.09	0.06	3.48	-0.21	-0.29
-623	-791	-936	-950	-1,147	-1,287	-1,223	-1,300	-1,220	-1,724	-1,896	-2,107	-2,049	-2,598	-3,345	-3,941	-4,486	-5,368	-6,030	-6,100	-6,810	-6,643	-6,475	-6,495	-6,966	-6,645	-6,987	-7,368	-7,506	-7,255	-7,624	-7,818
-0.59	2.36	2.97	-4.18	-0.85	-0.25	1.49	1.39	-0.75	-0.15	0.44	0.24	-2.51	1.55	-3.32	0.86	2.43	-1.61	1.84	1.14	6.34	-8.35	2.33	1.85	4.41	-2.16	-1.45	2.75	-4.89	5.88	-1.93	-0.02
1,465.41	934.99	1,850.98	2,156.21	2,950.96	3,674.11	3,708.72	2,972.52	3,632.36	5,109	5,145	6,536	6,527	13,676	7,348	9,458	11,835	11,922	11,126	9,796	10,493	8,392	8,596	10,327	11,624	11,368	11,065	12,100	11,565	11,705	13,805	15,244
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Unlock the full history with 30+ years of data and forecast estimates.

Unlock all data — PRO

API Docs Get API Key

Novartis Stock Quarterly Figures

REVENUE (B USD)

REVENUE GROWTH (%)

GROSS MARGIN (%)

GROSS INCOME (B USD)

NET INCOME (B USD)

NET INCOME GROWTH (%)

DIVIDEND (USD)DIV. (USD)

DIVIDEND GROWTH (%)DIV. GROWTH (%)

SHARES (B)

1998 Q2	1998 Q4	1999 Q2	1999 Q4	2000 Q2	2000 Q4	2001 Q1	2001 Q2	2001 Q3	2001 Q4	2002 Q1	2002 Q2	2002 Q3	2002 Q4	2003 Q1	2003 Q2	2003 Q3	2003 Q4	2004 Q1	2004 Q2	2004 Q3	2004 Q4	2005 Q1	2005 Q2	2005 Q3	2005 Q4	2006 Q1	2006 Q2	2006 Q3	2006 Q4	2007 Q1	2007 Q2	2007 Q3	2007 Q4	2008 Q1	2008 Q2	2008 Q3	2008 Q4	2009 Q1	2009 Q2	2009 Q3	2009 Q4	2010 Q1	2010 Q2	2010 Q3	2010 Q4	2011 Q1	2011 Q2	2011 Q3	2011 Q4	2012 Q1	2012 Q2	2012 Q3	2012 Q4	2013 Q1	2013 Q2	2013 Q3	2013 Q4	2014 Q1	2014 Q2	2014 Q3	2014 Q4	2015 Q1	2015 Q2	2015 Q3	2015 Q4	2016 Q1	2016 Q2	2016 Q3	2016 Q4	2017 Q1	2017 Q2	2017 Q3	2017 Q4	2018 Q1	2018 Q2	2018 Q3	2018 Q4	2019 Q1	2019 Q2	2019 Q3	2019 Q4	2020 Q1	2020 Q2	2020 Q3	2020 Q4	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2026 Q1e	2026 Q2e	2026 Q3e	2026 Q4e
11.3	10.56	11.22	10.41	8.46	12.67	4.35	4.6	4.8	5.02	4.76	4.83	5.4	3.59	5.72	6.2	6.21	6.73	6.67	13.67	7.1	7.63	7.41	7.87	22.85	8.47	7.76	8.67	9.02	9.65	9.37	9.58	9.82	10.17	10.22	10.99	11.03	10.35	9.93	10.74	11.29	13.15	12.36	11.92	12.82	14.46	14.22	15.12	15.03	15	13.91	14.54	14.04	15.07	12.9	13.28	12.91	13.63	13.03	13.95	13.3	13.35	12.17	12.9	12.49	12.8	11.81	12.68	12.34	12.56	11.79	12.49	12.69	13.16	11.15	11.63	11.36	11.88	11.4	12.02	12.48	12.72	12.71	11.62	12.54	13.03	12.69	13.29	13.37	4.62	12.81	21.71	10.78	10.88	11.05	11.75	12.09	11.78	12.12	12.87	13.17	13.56	13.59	14.53	14.36	13.86	13.82	14.48	14.45	14.41
–	-6.57	6.27	-7.24	-18.68	49.66	-65.66	5.75	4.41	4.50	-5.18	1.49	11.76	-33.46	59.31	8.43	0.11	8.37	-0.95	105.09	-48.07	7.46	-2.83	6.15	190.36	-62.94	-8.41	11.80	4.07	6.98	-2.90	2.24	2.44	3.60	0.44	7.58	0.36	-6.18	-4.08	8.22	5.10	16.43	-6.00	-3.52	7.54	12.82	-1.67	6.34	-0.59	-0.25	-7.22	4.51	-3.45	7.33	-14.37	2.93	-2.82	5.59	-4.38	7.04	-4.65	0.41	-8.84	5.93	-3.19	2.56	-7.76	7.36	-2.67	1.74	-6.14	6.02	1.58	3.72	-15.30	4.33	-2.36	4.56	-3.99	5.46	3.81	1.87	-0.06	-8.55	7.88	3.92	-2.58	4.73	0.55	-65.44	177.42	69.44	-50.34	0.90	1.53	6.32	2.95	-2.61	2.92	6.20	2.33	2.93	0.20	6.93	-1.16	-3.47	-0.28	4.75	-0.17	-0.26
68.30	68.29	68.42	71.11	75.27	68.91	74.06	76.02	75.36	74.79	74.72	76.33	75.69	78.39	76.18	77.06	75.85	76.11	74.66	74.75	75.14	73.12	74.02	74.90	74.21	72.06	74.47	74.34	71.97	72.27	73.46	73.95	69.10	70.38	74.08	73.28	72.61	72.61	73.96	73.71	72.52	72.10	74.94	73.11	71.44	68.72	68.65	69.46	68.15	65.87	67.77	68.30	67.41	66.24	69.48	69.22	68.03	67.51	68.31	68.61	66.76	66.93	67.55	66.37	65.23	64.88	64.56	65.15	65.08	64.75	65.52	66.30	66.18	66.63	69.05	69.41	69.51	66.00	72.24	72.43	71.03	69.85	72.03	71.29	71.54	69.76	69.80	71.76	71.21	223.38	70.70	73.90	73.35	72.05	72.92	71.55	74.22	74.63	74.50	75.38	75.39	75.56	76.27	77.15	75.38	74.44	74.65	71.27	71.39	71.58
7.72	7.21	7.68	7.4	6.37	8.73	3.22	3.5	3.62	3.75	3.56	3.69	4.09	2.82	4.36	4.78	4.71	5.12	4.98	10.22	5.34	5.58	5.49	5.9	16.96	6.1	5.78	6.45	6.5	6.98	6.89	7.09	6.78	7.16	7.57	8.05	8.01	7.51	7.34	7.92	8.19	9.48	9.26	8.72	9.16	9.94	9.76	10.5	10.25	9.88	9.43	9.93	9.46	9.98	8.96	9.19	8.78	9.2	8.9	9.57	8.88	8.94	8.22	8.56	8.14	8.31	7.63	8.26	8.03	8.13	7.72	8.28	8.4	8.77	7.7	8.08	7.9	7.84	8.24	8.71	8.87	8.88	9.15	8.29	8.97	9.09	8.86	9.54	9.52	10.32	9.06	16.05	7.91	7.84	8.06	8.4	8.98	8.79	9.03	9.7	9.93	10.24	10.36	11.21	10.82	10.32	10.32	10.32	10.32	10.32
2.39	1.74	2.54	1.9	2.06	2.21	0.89	1.28	1	0.98	1.07	1.2	1.19	0.74	1.06	1.32	1.28	1.36	1.24	2.77	1.47	1.35	1.48	1.64	4.78	1.35	1.95	1.71	1.87	1.65	2.17	2.01	6.87	0.9	2.32	2.25	2.09	1.54	1.96	2.04	2.1	2.31	2.93	2.42	2.28	2.17	2.77	2.7	2.46	1.18	2.25	2.65	2.39	1.99	2.4	2.52	2.23	2.03	2.94	2.56	3.22	1.49	13.01	1.84	1.89	1.05	2.01	1.8	1.94	0.96	1.67	1.98	2.08	1.98	2.03	7.77	1.62	1.2	1.77	6.8	2.04	1.13	2.18	1.87	1.94	2.09	2.06	2.9	2.76	16.31	2.22	3.92	1.57	1.47	2.29	2.32	1.76	8.48	2.69	3.25	3.19	2.82	3.61	4.04	3.93	2.41	4.28	4.52	4.42	3.98
–	-27.41	46.29	-25.07	8.04	7.54	-59.58	43.51	-22.45	-1.61	8.99	12.00	-0.17	-37.89	43.45	23.80	-2.96	6.50	-9.04	123.52	-46.84	-8.10	9.62	10.74	191.46	-71.76	44.22	-12.33	9.37	-11.41	31.14	-7.42	241.88	-86.83	156.31	-2.93	-7.07	-26.36	27.49	3.72	3.10	9.87	27.25	-17.59	-5.88	-4.66	27.71	-2.38	-8.88	-52.31	91.23	17.85	-9.74	-16.95	20.81	4.92	-11.29	-9.09	44.95	-13.12	26.14	-53.74	772.23	-85.88	2.83	-44.17	90.80	-10.29	7.54	-50.67	74.09	18.85	5.10	-5.05	2.48	283.60	-79.11	-26.37	47.78	284.99	-69.97	-44.91	93.42	-14.20	3.64	8.22	-1.67	40.65	-4.77	491.30	-86.37	76.24	-59.83	-6.80	56.41	1.00	-23.96	381.54	-68.30	20.76	-1.76	-11.63	27.96	12.06	-2.80	-38.67	77.63	5.63	-2.21	-10.00
-	-	-	-	-	-	0.71	-	-	-	0.75	-	-	-	0.79	-	-	0.83	-	-	-	-	0.88	-	-	-	0.96	-	-	-	1.13	-	-	-	1.33	-	-	-	1.67	-	-	-	1.75	-	-	-	1.83	-	-	-	1.88	-	-	-	1.92	-	-	-	2.04	-	-	-	2.17	-	-	-	2.25	-	-	-	2.29	-	-	-	2.33	-	-	-	2.38	-	-	-	2.46	-	-	-	2.50	-	-	-	2.58	-	-	-	2.67	-	-	-	3.30	-	-	-	3.50	-	-	-	3.70	-	-	-
–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
2.72	2.65	2.66	2.69	2.62	2.62	2.6	2.57	2.58	2.56	2.55	2.68	2.53	2.53	2.53	2.53	2.5	2.47	2.37	2.38	2.36	2.35	2.33	2.33	2.34	2.34	2.36	2.36	2.36	2.36	2.36	2.35	2.32	2.29	2.27	2.29	2.28	2.28	2.28	2.28	2.29	2.24	2.29	2.3	2.3	2.31	2.3	2.43	2.45	2.44	2.44	2.44	2.45	2.45	2.49	2.49	2.48	2.47	2.47	2.47	2.46	2.46	2.45	2.45	2.44	2.42	2.4	2.4	2.4	2.39	2.39	2.37	2.36	2.36	2.35	2.35	2.34	2.34	2.34	2.33	2.3	2.31	2.29	2.3	2.3	2.28	2.27	2.24	2.25	2.26	2.24	2.2	2.18	2.16	2.12	2.1	2.08	2.07	2.06	2.05	2.03	2.01	1.98	1.96	1.94	1.93	1.93	1.93	1.93	1.93

Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Gross Margin

EBIT and EBIT Margin

Net Income and Earnings Per Share (EPS)

Shares Outstanding

Analyst Estimates

Unlock the full history with 30+ years of data and forecast estimates.

Unlock all data — PRO

API Docs Get API Key

Novartis stock margins

The Novartis margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Novartis. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Novartis.

3 Years
5 Years
10 Years
25 Years
Max

Gross margin

EBIT margin

Profit margin

Details

API Docs Get API Key

Novartis Stock Sales Revenue, EBIT, Earnings per Share

The Novartis earnings per share therefore indicates how much revenue Novartis has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

3 Years
5 Years
10 Years
25 Years
Max

Sales per Share

EBIT per share

Earnings per Share

Details

API Docs Get API Key

Novartis business model

Novartis AG is a globally active company operating in the pharmaceutical, ophthalmology, and generics manufacturing sectors. The company, headquartered in Basel, Switzerland, was founded in 1996 and originated from a merger between Ciba-Geigy and Sandoz. Novartis AG is now a leading company worldwide in the research, development, production, and marketing of pharmaceuticals and other health products.

API Docs Get API Key

Novartis SWOT Analysis

Strengths

[ { "heading": "1.", "text": "Strong" }, { "heading": "2.", "text": "Diverse" }, { "heading": "3.", "text": "Solid" } ]

Weaknesses

[ { "heading": "1.", "text": "Dependence" }, { "heading": "2.", "text": "Product" }, { "heading": "3.", "text": "Limited" } ]

Opportunities

[ { "heading": "1.", "text": "Growing" }, { "heading": "2.", "text": "Expansion" }, { "heading": "3.", "text": "Acquisitions" } ]

Threats

[ { "heading": "1.", "text": "Intense" }, { "heading": "2.", "text": "Stringent" }, { "heading": "3.", "text": "Potential" } ]

API Docs Get API Key

Novartis Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

API Docs Get API Key

Novartis historical P/E ratio, EBIT multiple, and P/S ratio

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Novartis's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Novartis's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Novartis's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Novartis grows earnings faster than its peers.

API Docs Get API Key

Novartis annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

API Docs Get API Key

Novartis shares outstanding

The number of shares was Novartis in 2025 — This indicates how many shares 1.955 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

3 Years
5 Years
10 Years
25 Years
Max

Number of stocks

Details

API Docs Get API Key

Novartis stock splits

In Novartis's history, there have been no stock splits.

API Docs Get API Key

Novartis Dividend History

30 years of dividend payments · 23 consecutive increases

YearAnnual DividendYoY ChangePayments

20263.7USDYTD—1×

Mar 10, 20263.7USD↑ 5.7%1/1

20253.5USD↑ 6.1%1×

Mar 11, 20253.5USD↑ 6.1%1/1

20243.3USD↑ 3.1%1×

API Docs Get API Key

Novartis dividend history and estimates

In 2025, Novartis paid a dividend amounting to 3.5 USD. Dividend means that Novartis distributes a portion of its profits to its owners.

3 Years
5 Years
10 Years
25 Years
Max

Dividend

Dividend (Estimate)

Details

API Docs Get API Key

Novartis dividend payout ratio

In 2025, Novartis had a payout ratio of 64.89%. The payout ratio indicates the percentage of the company's profits that Novartis distributes as dividends.

3 Years
5 Years
10 Years
25 Years
Max

Payout ratio

Details

API Docs Get API Key

Current Novartis forecasts and price targets in March 2026

Δ MOM Price Target	5.45 %
Buy	50.00 % (17)
Hold	38.24 % (13)
Sell	11.76 % (4)
12M Price Target	152.48
Last Price	108.10
Currency	USD
12M Return Potential	41.06 %
LTM Return	0 %

API Docs Get API Key

Unlock Earnings — PRO

Novartis Earnings Estimates

Date	EPS estimate	Revenue Estimate	Quarterly report
10/25/2022	1.58USD	13.04 BUSD	2022 Q3
7/19/2022	1.53USD	13.04 BUSD	2022 Q2
4/26/2022	1.47USD	12.88 BUSD	2022 Q1
2/2/2022	1.45USD	13.55 BUSD	2021 Q4
10/26/2021	1.68USD	13.22 BUSD	2021 Q3
7/21/2021	1.57USD	12.71 BUSD	2021 Q2
4/27/2021	1.59USD	12.71 BUSD	2021 Q1
1/26/2021	1.4USD	13.08 BUSD	2020 Q4
10/27/2020	1.48USD	12.76 BUSD	2020 Q3
7/21/2020	1.35USD	12.07 BUSD	2020 Q2
4/28/2020	1.42USD	12.19 BUSD	2020 Q1
1/29/2020	1.33USD	12.46 BUSD	2019 Q4
10/22/2019	1.37USD	12.01 BUSD	2019 Q3
7/18/2019	1.25USD	11.69 BUSD	2019 Q2
4/24/2019	1.17USD	11.54 BUSD	2019 Q1
1/30/2019	1.3USD	13.51 BUSD	2018 Q4
10/18/2018	1.32USD	13.17 BUSD	2018 Q3
7/18/2018	1.3USD	13.17 BUSD	2018 Q2
4/19/2018	1.29USD	12.81 BUSD	2018 Q1
1/24/2018	1.2USD	12.97 BUSD	2017 Q4
10/24/2017	1.27USD	12.51 BUSD	2017 Q3
7/18/2017	1.21USD	12.45 BUSD	2017 Q2
4/25/2017	1.14USD	11.84 BUSD	2017 Q1
1/25/2017	1.13USD	12.56 BUSD	2016 Q4
10/25/2016	1.22USD	12.4 BUSD	2016 Q3
7/19/2016	1.21USD	12.51 BUSD	2016 Q2
4/21/2016	1.16USD	12.09 BUSD	2016 Q1
1/27/2016	1.22USD	13.03 BUSD	2015 Q4
10/27/2015	1.31USD	12.93 BUSD	2015 Q3
7/21/2015	1.31USD	12.9 BUSD	2015 Q2
4/23/2015	1.17USD	12.79 BUSD	2015 Q1
1/27/2015	1.22USD	14.52 BUSD	2014 Q4
10/28/2014	1.34USD	14.49 BUSD	2014 Q3
7/17/2014	1.4USD	15.12 BUSD	2014 Q2
4/24/2014	1.32USD	14.49 BUSD	2014 Q1
1/29/2014	1.25USD	15.23 BUSD	2013 Q4
10/22/2013	1.29USD	14.54 BUSD	2013 Q3
7/17/2013	1.37USD	14.55 BUSD	2013 Q2
4/24/2013	1.31USD	14.21 BUSD	2013 Q1
1/23/2013	1.28USD	14.81 BUSD	2012 Q4
10/25/2012	1.38USD	14.3 BUSD	2012 Q3
7/19/2012	1.36USD	14.5 BUSD	2012 Q2
4/24/2012	1.32USD	14.07 BUSD	2012 Q1
1/25/2012	1.28USD	14.91 BUSD	2011 Q4
10/25/2011	1.5USD	15.07 BUSD	2011 Q3
7/19/2011	1.48USD	14.75 BUSD	2011 Q2
4/19/2011	1.34USD	13.86 BUSD	2011 Q1
1/27/2011	1.22USD	14.21 BUSD	2010 Q4
10/21/2010	1.21USD	12.56 BUSD	2010 Q3
7/15/2010	1.17USD	11.63 BUSD	2010 Q2
4/20/2010	1.26USD	11.75 BUSD	2010 Q1
1/26/2010	1.17USD	12.17 BUSD	2009 Q4
10/22/2009	1.01USD	11.17 BUSD	2009 Q3
7/16/2009	0.92USD	10.41 BUSD	2009 Q2
4/23/2009	0.86USD	9.73 BUSD	2009 Q1
1/28/2009	0.85USD	10.41 BUSD	2008 Q4
10/20/2008	0.92USD	10.66 BUSD	2008 Q3
7/17/2008	0.96USD	10.35 BUSD	2008 Q2
4/21/2008	0.86USD	9.84 BUSD	2008 Q1
1/17/2008	0.68USD	9.32 BUSD	2007 Q4
10/18/2007	0.77USD	9.45 BUSD	2007 Q3
7/17/2007	0.85USD	9.48 BUSD	2007 Q2
4/23/2007	0.83USD	9.38 BUSD	2007 Q1
1/18/2007	0.75USD	9.81 BUSD	2006 Q4
10/19/2006	0.77USD	9.48 BUSD	2006 Q3
7/17/2006	0.83USD	9.19 BUSD	2006 Q2
4/24/2006	0.73USD	8.72 BUSD	2006 Q1
1/19/2006	0.6USD	8.27 BUSD	2005 Q4
10/18/2005	0.65USD	8.35 BUSD	2005 Q3
8/2/2005	0.7USD	7.96 BUSD	2005 Q2
4/22/2005	0.62USD	7.61 BUSD	2005 Q1
1/20/2005	0.58USD	7.46 BUSD	2004 Q4
10/21/2004	0.62USD	7.2 BUSD	2004 Q3

...

EESG©

Eulerpool ESG Scorecard© for the Novartis stock

84/100

Environment

Social

Governance

Environment

Scope 1 - Direct Emissions207,000

Scope 2 - Indirect emissions from purchased energy200,400

Scope 3 - Indirect emissions within the value chain4,350,300

Total CO₂ emissions407,400

CO₂ reduction strategy

Coal energy

Nuclear power

Animal experiments

Fur & Leather—

Pesticides—

Palm Oil—

Tobacco

Genetically modified organisms

Climate concept—

Sustainable forestry—

Recycling regulations

Environmentally friendly packaging

Hazardous substances

Fuel consumption and efficiency

Water consumption and efficiency

Social

Percentage of female employees52

Percentage of women in management—

Percentage of Asian employees—

Share of Asian management—

Percentage of Hispanic/Latino employees—

Hispano/Latino Management share—

Percentage of Black employees—

Black Management Share—

Percentage of white employees—

White Management Share—

Adult content

Alcohol

Weapons—

Firearms

Gambling

Military contracts

Human rights concept

Privacy concept—

Occupational health and safety

Catholic

Governance (Corporate Governance)

Environmental reporting

Stakeholder Engagement

Call Back Policies

Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

API Docs Get API Key

Novartis shareholders

%	Name	Stocks	Change	Date
7.13003%	BlackRock Institutional Trust Company, N.A.	139,392,071	+8,398,901	12/31/2024
5.93294%	UBS Asset Management (Switzerland)	115,988,883	-2,498,584	12/31/2024
3.31466%	The Vanguard Group, Inc.	64,801,627	+56,025	7/31/2025
2.57639%	Norges Bank Investment Management (NBIM)	50,368,401	-4,291,065	12/31/2024
1.46729%	BlackRock Advisors (UK) Limited	28,685,562	+411,246	7/31/2025
1.44436%	Zürcher Kantonalbank (Asset Management)	28,237,191	-1,640	7/31/2025
0.89051%	Geode Capital Management, L.L.C.	17,409,558	+1,345	7/31/2025
0.83080%	Artisan Partners Limited Partnership	16,242,051	+988,384	6/30/2025
0.70931%	GQG Partners, LLC	13,867,038		5/31/2025
0.70925%	DWS Investment GmbH	13,865,934	+86,180	7/31/2025
0.66589%	Dodge & Cox	13,018,170	-934,700	6/30/2025
0.65596%	Wellington Management Company, LLP	12,824,084	+15	7/31/2025
0.61808%	BlackRock Investment Management (UK) Ltd.	12,083,452	-195,943	6/30/2025
0.60037%	Pictet Asset Management Ltd.	11,737,267	+35,807	6/30/2025
0.42988%	California Public Employees' Retirement System	8,404,139	-1,854,662	6/30/2024
0.37047%	UBS Asset Management (UK) Ltd.	7,242,734	-866,535	7/31/2025
0.35856%	Fidelity International	7,009,886	+115,067	6/30/2025
0.33861%	Charles Schwab Investment Management, Inc.	6,619,747	+23,901	7/31/2025
0.32189%	MFS Investment Management	6,292,863	+192,227	6/30/2025
0.31074%	DWS Investments UK Limited	6,074,997	+1,512,605	7/31/2025
0.30958%	Vontobel Asset Management AG	6,052,338	-221,638	4/30/2025
0.30841%	Deka Investment GmbH	6,029,434	+32,465	7/31/2025
0.30223%	Nuveen LLC	5,908,559	-30,987	7/31/2025
0.29683%	CPP Investment Board	5,803,000	+1,400,000	3/31/2024
0.28844%	JPMorgan Asset Management U.K. Limited	5,639,006	-735	7/31/2025
0.27840%	APG Asset Management N.V.	5,442,750	+723,739	12/31/2024
0.25970%	UBS Asset Management Switzerland AG	5,077,128	+122,937	7/31/2025
0.24388%	State Street Global Advisors (UK) Ltd.	4,767,922	+8,115	7/31/2025
0.21411%	Amundi Asset Management, SAS	4,185,842	+16,767	7/31/2025
0.20954%	Aviva Investors Global Services Limited	4,096,479	-12,246	6/30/2025
0.20818%	State Street Global Advisors (US)	4,069,881	+12,095	7/31/2025
0.19519%	T. Rowe Price International Ltd	3,815,899	+967	7/31/2025
0.19296%	BlackRock Asset Management Deutschland AG	3,772,368	-5,782	7/31/2025
0.17468%	HSBC Global Asset Management (UK) Limited	3,414,962	-6,448	6/30/2025
0.17228%	Banque Cantonale Vaudoise	3,368,142	+1,448	6/30/2025
0.16865%	Allianz Global Investors GmbH	3,297,180	-142,364	6/30/2025
0.16638%	BlackRock Financial Management, Inc.	3,252,728		7/31/2025
0.15125%	California State Teachers Retirement System	2,956,886	+60,260	6/30/2024
0.15031%	Capital Research Global Investors	2,938,571	-7,346	6/30/2025
0.14058%	Legal & General Investment Management Ltd.	2,748,364	+14,298	7/31/2025
0.13705%	Eleva Capital SAS	2,679,260	+240,382	4/30/2025
0.13490%	Swiss Life Asset Management	2,637,340	+3,300	6/30/2025
0.13348%	Caisse de Depot et Placement du Quebec	2,609,558	+530,661	12/31/2024
0.13281%	JP Morgan Asset Management	2,596,457	+3,104	7/31/2025
0.13209%	PGGM Vermogensbeheer B.V.	2,582,344	-44,931	3/31/2025
0.13136%	Dimensional Fund Advisors, L.P.	2,568,153	+10,847	7/31/2025
0.12668%	Northern Trust Global Investments Limited	2,476,519	+415,729	6/30/2025
0.12497%	Schroder Investment Management Ltd. (SIM)	2,443,149	+211,520	6/30/2025
0.11702%	DWS International GmbH	2,287,770	+5,795	6/30/2025
0.10245%	Candriam Luxembourg S.A.	2,002,850	-107,216	6/30/2025
0.09872%	Mercier Van Lanschot NV	1,930,034	+3,717	6/30/2025
0.09386%	Northern Trust Investments, Inc.	1,834,986	+7,707	7/31/2025
0.09292%	DBX Advisors LLC.	1,816,531	-25,652	7/31/2025
0.09128%	Union Investment Privatfonds GmbH	1,784,564	-1,340,800	12/31/2024
0.09119%	Vanguard Global Advisers LLC	1,782,849	-65,219	6/30/2025
0.08915%	AllianceBernstein L.P.	1,742,852	+46,167	7/31/2025
0.08764%	Basler Kantonalbank	1,713,439	-49,570	7/31/2025
0.08656%	GAM Investment Management (Switzerland) AG	1,692,333	-1,499	6/30/2025
0.08638%	BCGE Asset Management	1,688,780	-1,300	4/30/2025
0.08067%	TD Asset Management Inc.	1,577,146	+87,344	6/30/2025
0.07978%	Nordea Funds Oy	1,559,783	+62,667	6/30/2025
0.07949%	Basellandschaftliche Kantonalbank	1,554,074	-8,000	6/30/2025
0.07730%	Union Bancaire Privée, UBP SA	1,511,127	-18,969	4/30/2025
0.07722%	Berner Kantonalbank AG	1,509,557	+54,100	4/30/2025
0.07603%	Florida State Board of Administration	1,486,312	-315,576	3/31/2025
0.07516%	BMO Asset Management Inc.	1,469,305	-14,156	7/31/2025
0.07422%	SEB Investment Management AB	1,451,018	+34,000	6/30/2025
0.07287%	Harris Associates L.P.	1,424,587	-120,400	6/30/2025
0.07199%	BlackRock Asset Management Canada Limited	1,407,462	+33,793	7/31/2025
0.07001%	Goldman Sachs Asset Management, L.P.	1,368,700	+807	7/31/2025
0.06948%	Independent Franchise Partners LLP	1,358,359	+68,606	3/31/2025
0.06921%	Tweedy, Browne Company LLC	1,353,108	-94,280	6/30/2025
0.06574%	AQR Capital Management, LLC	1,285,257	+204,036	6/30/2025
0.06395%	Storebrand Kapitalforvaltning AS	1,250,210	+1,941	6/30/2025
0.06221%	Goldman Sachs Asset Management International	1,216,270	+1	6/30/2025
0.06117%	Schroder Investment Management (Switzerland) AG	1,195,800	-46,000	6/30/2025
0.06084%	Capfi Delen Asset Management	1,189,426	-142,067	3/31/2025
0.06020%	Vanguard Investments Australia Ltd.	1,176,887	-13,832	6/30/2025
0.05844%	Graubündner Kantonalbank	1,142,576	-8,000	6/30/2025
0.05783%	BNP Paribas Asset Management UK Limited	1,130,618	-26,174	6/30/2025
0.05771%	Danske Bank Asset Management	1,128,238	+164	7/31/2025
0.05752%	Handelsbanken Kapitalförvaltning AB	1,124,547	+29,845	6/30/2025
0.05445%	Harding Loevner LP	1,064,546	+1,063,459	6/30/2025
0.05424%	Eurizon Capital SGR S.p.A.	1,060,311	+123,314	6/30/2025
0.05388%	IST Investmentstiftung	1,053,432	+36,855	6/30/2025
0.05374%	Ilmarinen Mutual Pension Insurance Company	1,050,577	+1,050,577	12/31/2024
0.05344%	Cardano Asset Management NV	1,044,677	+9,838	6/30/2025
0.05097%	Migros Bank Asset Management	996,510	+27,120	4/30/2025
0.05039%	Janus Henderson Investors	985,133	-720,116	6/30/2025
0.04941%	Franklin Advisers, Inc.	965,884	+16,241	7/31/2025
0.04925%	Valiant Bank AG	962,818	+18,410	5/31/2025
0.04860%	Fisher Investments	950,200		6/30/2025
0.04853%	LLB Swiss Investment AG	948,825	-138,516	6/30/2025
0.04623%	RBC Global Asset Management (UK) Limited	903,797	+903,797	6/30/2025
0.04578%	Albin Kistler AG	895,000		4/30/2025
0.04538%	Thrivent Asset Management, LLC	887,108	+41,298	5/31/2025
0.04454%	Robeco Institutional Asset Management B.V.	870,680	-91,342	6/30/2025
0.04291%	Mellon Investments Corporation	838,914	+22,279	7/31/2025
0.04285%	zCapital AG	837,800	+1,000	6/30/2025
0.04163%	Mackenzie Investments	813,831	-1,127	7/31/2025

...

API Docs Get API Key

Novartis Executives and Management Board

Dr. Vasant Narasimhan

(49)

Chief Executive Officer, Member of the Executive Committee

Compensation19.17 MUSD

Compensation19.17 M USD

Mr. Harry Kirsch

(60)

Chief Financial Officer, Member of the Executive Committee

5.43 MUSD

Compensation5.43 M USD

Mr. Aaron Gal

(59)

Chief Strategy and Growth Officer, Member of the Executive Committee

5.32 MUSD

Compensation5.32 M USD

Dr. Fiona Marshall

(61)

President - Biomedical Research, Member of the Executive Committee

4.37 MUSD

Compensation4.37 M USD

Dr. Steffen Lang

(58)

President - Operations, Member of the Executive Committee

3.86 MUSD

Compensation3.86 M USD

API Docs Get API Key

Novartis Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite

30 companies

#	Name	1M	3M	6M	1Y	2Y	Trend
1	Basware Supplier	0,74	0,84	0,49	0,55	0,32

#	Name	1M	3M	6M	1Y	2Y
1	908 Devices Supplier	0,77	-0,56	-0,66	0,07	—
2	Morimatsu International Holdings Supplier	0,79	-0,19	-0,66	—	—
3	Snowflake A Supplier	0,76	-0,78	-0,78	-0,60	—
4	Valeo Pharma A Supplier	0,60	—	—	—	—
5	Xencor Supplier	0,69	-0,76	-0,71	-0,56	-0,22

API Docs Get API Key

Novartis Research

Soon

Deep-dive analyses, investment theses, and proprietary research — curated by Eulerpool.

Research reports are coming soon

We're building institutional-grade equity research for Novartis and thousands of other companies.

Most common questions regarding Novartis

The business model of Novartis AG focuses on the development, manufacturing, and commercialization of innovative healthcare solutions. As one of the leading pharmaceutical companies globally, Novartis AG operates in three main segments: Pharmaceuticals, which includes patented prescription medicines; Alcon, which deals with eye care products; and Sandoz, responsible for generic pharmaceuticals and biosimilars. Novartis AG strives to improve patient outcomes by investing heavily in research and development, collaborating with healthcare professionals, and implementing cutting-edge technologies. By combining scientific expertise with a patient-centric approach, Novartis AG aims to address unmet medical needs and contribute to the advancement of healthcare worldwide.

Novartis AG is an international pharmaceutical and biotechnology company based in Basel, Switzerland. The company has been listed on the New York Stock Exchange (NYSE) since 1996 and operates in four main segments: Pharma, Alcon, Sandoz, and Consumer Health. In the Pharma segment, Novartis offers a wide range of prescription drugs focused on various therapy areas such as oncology, neurology, cardiology, and immunology. In 2020, the Pharma segment accounted for approximately 64% of the company's total revenue. One of Novartis's most well-known drugs is the cancer medication Glivec, which generated sales of nearly $3.3 billion in 2020. Novartis's Alcon segment is a leading provider of ophthalmology products and services. The segment offers a wide range of products, from contact lenses to surgical instruments and devices. In 2020, Alcon contributed approximately 18% to the company's total revenue. Some of Alcon's well-known products include the contact lens brands Air Optix and Dailies, as well as the Verion surgical system. The Sandoz segment of Novartis specializes in the development, manufacturing, and marketing of generics and biosimilars. Biosimilars are copies of biological drugs that are already on the market. The Sandoz segment offers a wide range of medications, from painkillers to cancer drugs. In 2020, Sandoz accounted for approximately 11% of the company's total revenue. Novartis's Consumer Health segment offers a wide range of over-the-counter (OTC) health products focused on dermatology, ophthalmology, and orthopedics. Consumer Health products are available in more than 140 countries. Some of the well-known brands of Consumer Health include Voltaren, Excedrin, and Nicotinell. In 2020, Consumer Health contributed approximately 7% to the company's total revenue. Novartis heavily invests in research and development (R&D) to develop new products and therapies. In 2020, Novartis spent nearly $10 billion on R&D, which represents approximately 18% of its revenue. The company collaborates closely with external partners to develop and bring innovative therapies to the market. To achieve growth, Novartis also relies on targeted acquisitions. In 2020, the company acquired US biotech company The Medicines Company for $9.7 billion to strengthen its activities in the cardiovascular disease area. Overall, Novartis pursues a diversified business model based on a strong presence in various therapy areas and geographical regions. The company focuses on investments in R&D and targeted acquisitions to drive its growth.

API Docs Get API Key

Fair ValuePRO

140.43 USD

Over-/UndervaluationPRO

30.0% undervalued

Expected Return

8.84 %

Sector

Health

Industry

Pharmaceuticals

Number of shares

1,955,000,000

Employees

109,000

Revenue per Employee

516,788.99 USD

Revenue growth Ø5 years

5.08 %

EBIT growth Ø5 years

11.26 %

Net Income growth Ø5 years

-10.26 %

Website novartis.com

Country

Switzerland 🇨🇭

Currency

USD

Initial public offering

May 7, 2001

ISIN

CH0012005267

Cusip

H5820Q150

Sedol

7103065

Market capitalization

309.47 B USDMega Cap

52-Week Range

152.45–167.79USD

Novartis Directors Dealings

Quality Investing

Details

8 / 10

Sales growth (10Y) > 5%

Revenue growth (3Y) > 5 %

EBIT growth (10Y) > 5%

EBIT growth (3Y) > 5 %

Net debt < 4x EBIT

Profitable since 10Y+

EBIT Drawdown (10Y) < 50%

Return on Equity (ROE) > 15%

ROCE > 15%

Return Expectation > 10%

PEG

5.01

P/E ratio

22.83

P/Ee 2026

17.51

P/Ee 2027

16.33

P/Ee 2028

14.62

P/Ee 2029

14.11

P/Ee 2030

13.41

P/S

5.67

P/Se

5.49

EV/EBIT

17.84

P/B Ratio

6.71

ROE (Return on Equity)

30.31 %

ROA (Return on Assets)

12.6 %

ROCE (Return on Capital Employed)

40.52 %

ROIC (Return on Invested Capital)

19.96 %

PROUnlock all valuation metrics

Gross Margin

75.82 %

EBIT Margin

33.18 %

Net Margin

24.83 %

EPS (Earnings Per Share)

7.15 USD

Net Debt / EBIT

1.28

Debt/Equity

0.77

Dividend

3.5 USD

Dividend yield

2.14 %

Est. Dividend Yield

2.27 %

Payout Ratio

64.89 %

Dividend growth Ø5Y

3.6 %

Dividend payments per year

Dividend paid since

21 years+

Dividend not reduced since

20 years+

Dividend increased since

20 years+

Dividend withholding tax

35 %

Last updated Mar 7, 2026, 5:35 AM

Novartis Peer Group

Roche Holding AG

Auris Medical Holding Ltd

Vifor Pharma AGPRO

Novartis Ticker

DÜSSELDORF · NOT.DUFRANKFURT · NOT.FHAMBURG · NOT.HMLONDON · 0QLR.LMUNICH · NOT.MUPNK · NVSEFSIX · NOVN.SW

Novartis FIGI

NVSEF:US · BBG000KSBX82NVSEF:PQ · BBG000KSD652NVSEF:UV · BBG000KSD796NOVN:SW · BBG000NQV2C4NOT:GR · BBG000P33LR6NOT:GF · BBG000P33P33NOT:GD · BBG000P33Q04NOT:GS · BBG000P33QR5NOT:GM · BBG000P33R75NOT:GB · BBG000P33RJ2NOT:GI · BBG000P33T71NOT:GH · BBG000P33TJ8NOVNZ:IX · BBG000Q8M8B9NOVN:EO · BBG000QPRCW4NOVN:XH · BBG000QPRFB0NOVN:XC · BBG000QPRFQ4NOVN:XF · BBG000QPRFV8NOVN:XE · BBG000QPRGJ0NOVN:XJ · BBG000QPRGQ2NOVN:XL · BBG000QPRH62NOVN:XG · BBG000QPRHK6NOVN:XO · BBG000QPRJG7NOVN:XS · BBG000QPRL63NOVN:XA · BBG000QPRM07NOVN:E1 · BBG000QPRMD3NOVN:XT · BBG000QPRMY0NOVN:XW · BBG000QPRNM1NOVN:EU · BBG000QPRP64NOVNEUR:EU · BBG000QYSVF1NOVNEUR:EO · BBG000QYSW14NOVNEUR:XH · BBG000QYSWR6NOVNEUR:XC · BBG000QYSXN8NOVNEUR:XF · BBG000QYSYC8NOVNEUR:XE · BBG000QYSZZ0NOVNEUR:XJ · BBG000QYT0B2NOVNEUR:XG · BBG000QYT1S2NOVNEUR:XO · BBG000QYT2H2NOVNEUR:XS · BBG000QYT4T5NOVNEUR:XA · BBG000QYT530NOVNEUR:E1 · BBG000QYT5G6NOVNEUR:XT · BBG000QYT5R4NOVNEUR:XW · BBG000QYT5Y6NOVNGBX:EU · BBG000QYX615NOVNGBX:EO · BBG000QYX6R7NOVNGBX:XH · BBG000QYX8D8NOVNGBX:XC · BBG000QYX8Y5NOVNGBX:XF · BBG000QYX9Z2NOVNGBX:XE · BBG000QYXBH7NOVNGBX:XJ · BBG000QYXC03NOVNGBX:XL · BBG000QYXCG6NOVNGBX:XG · BBG000QYXCQ5NOVNGBX:XO · BBG000QYXD65NOVNGBX:XS · BBG000QYXDR2NOVNGBX:XA · BBG000QYXFT5NOVNGBX:E1 · BBG000QYXG22NOVNGBX:XT · BBG000QYXGK2NOVNGBX:XW · BBG000QYXHK0NOVNGBP:EO · BBG000QZ6BT1NOVNGBP:E1 · BBG000QZ6KX6NOVNGBP:XT · BBG000QZ6LP3NOVNGBP:XW · BBG000QZ6LR1NOVV:PZ · BBG000R0RB96NOVNUSD:EO · BBG000R4T5L5NOVNUSD:E1 · BBG000R4TD74NOVNUSD:XT · BBG000R4TDG4NOVNUSD:XW · BBG000R4TDY4NOVNUSD:EU · BBG000R4TFM2NOVNZ:TQ · BBG000RGZJL1NOVNZ:EB · BBG000RL6DC5NOVNZ:S1 · BBG001MBXY61NOVN:XV · BBG00591DC05NOVNEUR:XV · BBG00591LPH9NOVNGBX:XV · BBG00591LRX7NOVNGBP:XV · BBG00591M1D5NOVNUSD:XV · BBG00591Q7W7NOVNZ:QX · BBG005HVCVY2NOTD:L3 · BBG006T9HCH2NOVNZ:L3 · BBG006T9HCM6NOTD:B3 · BBG006TBDRZ8NOVNZ:B3 · BBG006TBDS13NOT:QT · BBG0077HCBX5NOVN:BW · BBG008B4YSV8NOTD:PO · BBG008H07265NOVNZ:PO · BBG008H072L8NOT:GZ · BBG00FZMF271NOVN:SE · BBG00HCYS021NOVN:XM · BBG00J9VJ9C7NOVN:XX · BBG00JN7B004NOVNEUR:XX · BBG00JN7JBN7NOVNGBX:XX · BBG00JN7JF21NOVNGBP:XX · BBG00JN7JPK9NOVNUSD:XX · BBG00JN7MWV80QLR:LO · BBG00LPCB5S5NOVNCHF:T2 · BBG00N0069F6NOVNCHF:WT · BBG00NR8P2H2NOVNEUR:X2 · BBG00Q6R6N45NOTD:L1 · BBG00Y92H743NOVNZ:L1 · BBG00Y92H7R8NOVNRUB:XS · BBG0146V6PL0NOVNRUB:X2 · BBG0146V6PM9NOVNRUB:XH · BBG0146V6PQ5NOVNRUB:XF · BBG0146V6PT2NOVNRUB:XE · BBG0146V6PX7NOVNRUB:XJ · BBG0146V6PY6NOVNRUB:XL · BBG0146V6PZ5NOVNRUB:XG · BBG0146V6Q10NOVNRUB:XO · BBG0146V6Q38NOVNRUB:XA · BBG0146V6Q92NOVNRUB:E1 · BBG0146V6QB9NOVNRUB:XT · BBG0146V6QC8NOVNRUB:XW · BBG0146V6QF5NOVNRUB:XU · BBG0146V6QH3NOVNRUB:XV · BBG0146V6QL8NOVNRUB:XM · BBG0146V6QM7NOVNRUB:XQ · BBG0146V6QP4NOVNRUB:XX · BBG0146V6QR2NOVNRUB:XZ · BBG0146V6QS1NOVNRUB:X1 · BBG0146V6QV7NOVNRUB:EU · BBG0146V6RF3NOVNN:MM · BBG017NGCWQ0NOVNN:MF · BBG017NGCWR9NOVNN:MU · BBG017NGCWS8NOT:LA · BBG018H82W02NOT:LU · BBG018J1QYK3

All fundamentals about Novartis

Our stock analysis for Novartis Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Novartis Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Novartis Directors Dealings→

Novartis Stocks→

Novartis Market capitalization→

Novartis Debt→

Novartis Liabilities→

Novartis Equity→